ARTES presenting new development offer at BIOEurope Spring in Vienna

Langenfeld, Germany: – ARTES Biotechnology, the Germany-based recombinant cell line and process development specialist will once again participate in the annual BIOEurope Spring biotech industry partnering conference, this year in Vienna. The contract R&D offer is designed for partner interested in the development of vaccine candidates and bio-therapeutic proteins.

ARTES´ Technical Director, Dr. Volker Jenzelewski, will represent the company in numerous partnering meetings, presenting the company’s excellent expertise in cell line and process development solutions for biopharma products.

Vaccine development platforms

Dr. Jenzelewski will be outlining ARTES proprietary vaccine development platforms, METAVAX® and SplitCore.

METAVAX^® is ARTES´ proprietary vaccine development platform based on enveloped virus-like particles (eVLP´s) and is already applied to engineer effective, safe and affordable vaccines for human and animal health applications. ARTES´ new SplitCore platform complements this offer with an alternative capsid VLP (cVLP) approach. ARTES now offers the full range of nanoparticle based vaccine development, covering both capsid VLPs and envelope VLPs.

Protein production platforms

With proprietary microbial expression systems ARTES offers access to innovative and affordable solutions for the commercial manufacturing of vaccines, as well as therapeutic peptides and proteins, including single domain antibody fragments.

“I am looking forward to representing ARTES at BIOEurope Spring as a great place to share knowledge about our VLP platforms, protein expression technologies and development capacities,” commented Dr. Jenzelewski.

“We will use face to face meetings to encourage new collaborations aimed at development of highly immunogenic vaccines and bio-therapeutics based on our specialist cell lines and process development,” he added.

About ARTES Biotechnology

ARTES Biotechnology is a pharmaceutical contract research & development organization that provides cell line and process development for and manufacturing of bio-pharmaceutical products. The company is a well-established partner for many of the biggest names in the industry, with more than 20 years of business experience, a track record of products developed for and marketed by clients as well as safe, reliable and highly competitive microbial production platforms.

ARTES specializes in recombinant cell line, process and vaccine development from microbial expression systems, marketing the unique METAVAX® (dHepB-eVLP) and SplitCore (HepB-cVLP) technology in combination with yeast expression.

ARTES operates worldwide from its 850m2 S1 facilities in Langenfeld, from where it offers cell line engineering based on yeast (Hansenula polymorpha, syn. Pichia angusta; Saccharomyces cerevisiae) and bacterial (E. coli) expression platforms, lab scale up- and downstream process development, supply of non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support.

About BIO-Europe Spring 2019

BIO-Europe Spring^® a premier partnering conference that annually attracts an international “who’s who” from biotech, pharma and finance for high caliber networking.

The three-day event opens on March 25 at the Messe Wien Exhibition and Congress Center in Vienna.

Featuring EBD Group’s sophisticated partnering system, partneringONE^®, the event enables delegates to network with companies across the life science value chain, from large biotech and pharma companies to financiers and innovators.

The conference is expected to attract some 2,500 delegates and 70 exhibitors representing more than 1,400 companies from some 50 countries worldwide. It will feature more than 20 workshops and panels with more than 3,600 licensing opportunities posted.

The event is organized by EBD with more information at: https://ebdgroup.knect365.com/bioeurope-spring